Compare Amgen, Inc. (AMGN) vs Freshworks Inc (FRSH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs Freshworks Inc — how do they compare? Amgen, Inc. trades at $362.14 (market cap $196.12B), while Freshworks Inc trades at $10.43 (market cap $2.86B). The key difference: Amgen, Inc. is far larger — about 68.6× Freshworks Inc's market cap, and Amgen, Inc. pays a 2.77% dividend while Freshworks Inc pays none. Which is the better fit depends on your goals.
| AMGN | FRSH | |
|---|---|---|
Market Cap | $196.12B | $2.86B |
Sector | Health | Technology |
52-Week High | $388.16 | $14.77 |
52-Week Low | $271.18 | $6.88 |
Enterprise Value | $241.41B | $2.12B |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
FRSH trades at $10.36, down 0.38% on the day, with a bullish technical signal from moving averages and an overall analyst consensus split evenly between Buy and Hold. The company reported strong revenue growth to $838.81M in 2025, turning profitable with a net income of $183.72M, and recently announced Q2 2026 earnings will be released on August 4, 2026. Recent news highlights include a partnership with Vanquis and AI product enhancements.
Outlook remains positive with Wall Street projecting a 26% upside, supported by robust cash flow and margin expansion. Key risks include competitive pressures in SaaS and execution on AI initiatives. The stock presents a value opportunity given its P/E of 16.86 versus sector averages, but investors should monitor Q2 earnings for sustained momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Freshworks Inc
Freshworks Inc provides software as a service platform that enables small and medium-sized businesses to support customers through e-mail, phone, website, and social networks. It offers solutions that serve the needs of users in the CX and ITSM categories, and have also expanded its offering with Sales and Marketing automation products. These product offerings enable organizations to acquire, engage, and better serve their customers and employees.
Read more on FRSH →
